Drug Research
AstraZeneca and Orca Pharmaceuticals announce research collaboration to identify best-in-class ROR? inhibitors to treat auto-immune diseases
AstraZeneca and Orca Pharmaceuticals, a UK based biopharmaceutical company, today announced a three year collaboration to develop inhibitors of retinoic acid–related orphan nuclear receptor gamma (ROR?). Inhibitors of this receptor are believed to have potential against a wide range...
Drug Research
AstraZeneca supports crowd sourcing challenge to find new combination therapies for cancer
AstraZeneca is making available preclinical data from over 50 of its medicines as part of the DREAM Challenge, an open innovation competition, to find the most synergistic drug combinations with the potential to treat cancer. Public release of a...
Drug Research
Sanofi, Fraunhofer create new natural product center of excellence
French pharmaceutical firm Sanofi and Germany-based Fraunhofer-Gesellschaft have formed a natural product center of excellence to speed up the discovery and development of new therapies to treat infectious diseases. As part of the deal, Sanofi...
Drug Research
Galena Biopharma, Dr. Reddy’s partner for NeuVax in India
Galena Biopharma and Dr. Reddy's Laboratories have entered into a strategic development and commercialization partnership on NeuVax (nelipepimut-S) in India. NeuVax (nelipepimut-S) is the immunodominant nonapeptide derived from the extracellular domain of the HER2 protein...
Drug Research
Cellceutix provides updates on clinical trials and developments of Its anti-cancer, anti-psoriasis, and antibiotic compounds
Cellceutix, a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, today provides shareholders with an update on the current status of the Company's compounds in development. Kevetrin, anti-cancer compound in...
Drug Research
Mission Pharmacal introduces new oral spray for dry mouth
US-based pharmaceutical firm Mission Pharmacal has launched a new safe and effective protective oral spray called Aquoral that moistens and lubricates the mouth for up to four hours. Dry mouth (xerostomia), which affects about 25...
Drug Research
Alzheon to advance ALZ-801 into Phase II trial in patients with Alzheimer’s disease
Alzheon announced the launch of the company, the securing of initial private financing, and the signing of an exclusive license agreement to a novel clinical drug candidate for Alzheimer’s disease, a family of analogs, and a drug development platform...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
